HSP90AA1 and acute myeloid leukemia: Future work may involve in vivo testing of HAA2020, alone or with dinaciclib or other CDK inhibitors, and comparing the activity with AML-gold standard therapies like cytarabine, all of which could better the understanding of the relationship between Hsp90 and CDK inhibition in AML.